Riaz Nadeem, Blecua Pedro, Lim Raymond S, Shen Ronglai, Higginson Daniel S, Weinhold Nils, Norton Larry, Weigelt Britta, Powell Simon N, Reis-Filho Jorge S
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Nat Commun. 2017 Oct 11;8(1):857. doi: 10.1038/s41467-017-00921-w.
BRCA1 and BRCA2 are involved in homologous recombination (HR) DNA repair and are germ-line cancer pre-disposition genes that result in a syndrome of hereditary breast and ovarian cancer (HBOC). Whether germ-line or somatic alterations in these genes or other members of the HR pathway and if mono- or bi-allelic alterations of HR-related genes have a phenotypic impact on other cancers remains to be fully elucidated. Here, we perform a pan-cancer analysis of The Cancer Genome Atlas (TCGA) data set and observe that bi-allelic pathogenic alterations in homologous recombination (HR) DNA repair-related genes are prevalent across many malignancies. These bi-allelic alterations often associate with genomic features of HR deficiency. Further, in ovarian, breast and prostate cancers, bi-allelic alterations are mutually exclusive of each other. The combination of these two properties facilitates reclassification of variants of unknown significance affecting DNA repair genes, and may help personalize HR directed therapies in the clinic.Germline mutations in homologous recombination (HR) DNA repair genes are linked to breast and ovarian cancer. Here, the authors show that mutually exclusive bi-allelic inactivation of HR genes are present in other cancer types and associated with genomic features of HR deficiency, expanding the potential use of HR-directed therapies.
BRCA1和BRCA2参与同源重组(HR)DNA修复,是种系癌症易感基因,会导致遗传性乳腺癌和卵巢癌(HBOC)综合征。这些基因或HR通路的其他成员中的种系或体细胞改变,以及HR相关基因的单等位基因或双等位基因改变是否会对其他癌症产生表型影响,仍有待充分阐明。在此,我们对癌症基因组图谱(TCGA)数据集进行了泛癌分析,观察到同源重组(HR)DNA修复相关基因的双等位基因致病性改变在许多恶性肿瘤中普遍存在。这些双等位基因改变通常与HR缺陷的基因组特征相关。此外,在卵巢癌、乳腺癌和前列腺癌中,双等位基因改变相互排斥。这两个特性的结合有助于对影响DNA修复基因的意义未明变异进行重新分类,并可能有助于在临床中实现HR定向治疗的个性化。同源重组(HR)DNA修复基因中的种系突变与乳腺癌和卵巢癌有关。在此,作者表明HR基因的相互排斥的双等位基因失活存在于其他癌症类型中,并与HR缺陷的基因组特征相关,扩大了HR定向治疗的潜在应用。